Goldman Sachs’s IGC Pharma IGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.2K | Hold |
65,541
| – | – | ﹤0.01% | 6364 |
|
|
2025
Q4 | $18.4K | Hold |
65,541
| – | – | ﹤0.01% | 6346 |
|
|
2025
Q3 | $27.3K | Hold |
65,541
| – | – | ﹤0.01% | 6225 |
|
|
2025
Q2 | $20.1K | Hold |
65,541
| – | – | ﹤0.01% | 5984 |
|
|
2025
Q1 | $18.7K | Hold |
65,541
| – | – | ﹤0.01% | 5943 |
|
|
2024
Q4 | $22K | Hold |
65,541
| – | – | ﹤0.01% | 5892 |
|
|
2024
Q3 | $28K | Buy |
65,541
+46
| +0.1% | +$18 | ﹤0.01% | 5662 |
|
|
2024
Q2 | $28.4K | Hold |
65,495
| – | – | ﹤0.01% | 5498 |
|
|
2024
Q1 | $26.2K | Hold |
65,495
| – | – | ﹤0.01% | 5369 |
|
|
2023
Q4 | $18.3K | Sell |
65,495
-1
| -0% | – | ﹤0.01% | 5448 |
|
|
2023
Q3 | $23.5K | Sell |
65,496
-17
| -0% | -$6 | ﹤0.01% | 5340 |
|
|
2023
Q2 | $20.4K | Buy |
65,513
+10
| +0% | +$3 | ﹤0.01% | 5545 |
|
|
2023
Q1 | $22.2K | Buy |
65,503
+10
| +0% | +$4 | ﹤0.01% | 5654 |
|
|
2022
Q4 | $20.8K | Sell |
65,493
-8
| -0% | -$3 | ﹤0.01% | 5696 |
|
|
2022
Q3 | $28K | Buy |
65,501
+7
| +0% | +$4 | ﹤0.01% | 5875 |
|
|
2022
Q2 | $35K | Buy |
65,494
+11
| +0% | +$7 | ﹤0.01% | 6093 |
|
|
2022
Q1 | $62K | Sell |
65,483
-1,148
| -2% | -$1.11K | ﹤0.01% | 6224 |
|
|
2021
Q4 | $65K | Hold |
66,631
| – | – | ﹤0.01% | 6218 |
|
|
2021
Q3 | $99K | Sell |
66,631
-16,629
| -20% | -$26.9K | ﹤0.01% | 5910 |
|
|
2021
Q2 | $137K | Hold |
83,260
| – | – | ﹤0.01% | 5868 |
|
|
2021
Q1 | $149K | Hold |
83,260
| – | – | ﹤0.01% | 5746 |
|
|
2020
Q4 | $130K | Buy |
83,260
+16,980
| +26% | +$25.1K | ﹤0.01% | 5238 |
|
|
2020
Q3 | $69K | Sell |
66,280
-200
| -0.3% | -$203 | ﹤0.01% | 5144 |
|
|
2020
Q2 | $40K | Buy |
66,480
+200
| +0.3% | +$108 | ﹤0.01% | 5083 |
|
|
2020
Q1 | $32K | Hold |
66,280
| – | – | ﹤0.01% | 5094 |
|
|
2019
Q4 | $42K | Sell |
66,280
-1
| -0% | -$1 | ﹤0.01% | 5128 |
|
|
2019
Q3 | $64K | Buy |
66,281
+28,901
| +77% | +$34.8K | ﹤0.01% | 5018 |
|
|
2019
Q2 | $61K | Hold |
37,380
| – | – | ﹤0.01% | 5004 |
|
|
2019
Q1 | $78K | Buy |
+37,380
| New | +$85K | ﹤0.01% | 4954 |
|
|
2014
Q3 | – | Sell |
-10,437
| Closed | -$15K | – | 7173 |
|
|
2014
Q2 | $15K | Buy |
+10,437
| New | +$11.8K | ﹤0.01% | 6901 |
|
Other funds holding IGC
VCM
VFT
LC
DP
Goldman Sachs's IGC Position: Q1 2026 in Review
Goldman Sachs held its IGC Pharma (IGC) position steady in Q1 2026 at 65,541 shares worth $17.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6364.
Goldman Sachs first reported a position in IGC in Q2 2014 and has held it in 30 quarters since. The position peaked at $149K in Q1 2021. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.
- Goldman Sachs held 65,541 shares of IGC Pharma worth $17.2K as of Q1 2026.
- Goldman Sachs left its IGC Pharma share count unchanged in Q1 2026.
- IGC Pharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6364 holding.
- Goldman Sachs first reported a position in IGC Pharma in Q2 2014 and has held it in 30 quarters since.
- Goldman Sachs's IGC Pharma position peaked at $149K in Q1 2021.
- 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.